173results about How to "Low effective concentration" patented technology

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.

The invention belongs to the technical field of poultry yard disinfection, and particularly relates to a method for disinfecting a chicken farm. The method for disinfecting the chicken farm comprises the following steps of: chicken house disinfection, utensil disinfection, chicken farm disinfection and personnel disinfection. By adopting the method for disinfecting the chicken farm, the immunity of chickens is increased, good chickens are raised, and good economic benefit is gained; and the selected disinfectant has the advantages of broad disinfection spectrum, low effective concentration, quick response, no harm to people and animal and stable performance, is easily dissolved in water, is convenient to use and easy to popularize, and has little residue after use.

The invention discloses a soil improvement agent and improvement method of heavy metal lead-contaminated soil, relating to a soil improvement agent. The soil improvement agent is solid bamboo shoot shell-based biochar, and elements obtained by isolating oxygen at 400 DEG C and pyrolyzing for 30 minutes include C, H, N, K, P, Mg, Ca, Si and O. The soil improvement agent is prepared by the steps of cleaning, drying and grinding a bamboo shoot shell, and putting into a pyrolyzing furnace; isolating oxygen at 380-420 DEG C and pyrolyzing for 20-40 minutes; drying, pre-charring and charring the biomass bamboo shoot shell to obtain solid bamboo shoot shell-based biochar. The improvement method comprises the steps of adding 2.5-10% of the soil improvement agent by mass into the heavy metal lead-contaminated soil; adding water to 70% of the saturation moisture capacity of the field oil; covering with a film to prevent water loss; forming air ports in the film at an interval of 5cm; adding water every 2-3 days to supplement the lost water; culturing, taking out the product and performing air drying to obtain improved soil.

An IGBT includes a plurality of n⁺ doped regions (11) selectively formed in a main surface (103) of a p⁺ semiconductor layer (12) opposite from an n type semiconductor layer (80) without being connected to the n type semiconductor layer (80). The n⁺ doped regions (11) are formed in corresponding relation to and only under channel regions (CH1a-CH1d) of structures (200a-200d), respectively. This lowers the effective concentration of the p⁺ semiconductor layer (12) on the n⁺ doped regions (11) to reduce the number of holes injected from a collector layer (9) in an off state, reducing a leakage current.

Methods and compositions are disclosed for treating multiple sclerosis in a human subject by administering a therapeutically effective amount of an H4L4 antibody or a 2XCon4(C) peptibody.

The present invention relates to systems, methods and kits for low-level detection of nucleic acids, detecting at least two different viral sequences in a single reaction vessel, and increasing the dynamic range of detection of a viral target nucleic acid in a sample. The present invention also relates to T-structure invasive cleavage assays, as well as T-structure related target dependent non-target amplification methods and compositions. The present invention further relates to methods, compositions, devices and systems for consistent nucleic acid dispensing onto surfaces.

The invention relates to a fracturing technology for implementing the ultrahigh flow conductivity, which comprises the following steps: 1, judging whether geomechanics parameters of a target reservoir is suitable for the fracturing technology disclosed by the invention or not; 2, judging whether completion perforation of a target well is suitable for the fracturing technology disclosed by the invention or not, and if no, changing a perforating scheme of a well bottom; 3, before fracturing, selecting related fracturing materials; 4, carrying out fracturing on the target well by using a unique pumping program of the fracturing technology disclosed by the invention. According to the fracturing technology, proppant struts are formed in a stratum; flow conductivity of a stratum fracture is not improved by a filling layer of a proppant, but oil gas passes through by passages between the proppant struts; the flow conductivity is obviously improved by the open flowing passages; the flow conductivity of an existing conventional fracturing technology is not more than 200mum<2>*cm generally, but the flow conductivity of the fracturing technology for implementing the ultrahigh flow conductivity, which is disclosed by the invention, is higher than that of the conventional fracturing technology by 1 to 3 orders of magnitude; the fracturing technology reduces a pressure drop in the fracture, is helpful for improving drainage capacity and increases the effective fracture half-length and the production increase volume of the reservoir so as to improve yield.

The present invention aims to achieve both rapid supply of reagent substances to micro-chambers and inhibition of contamination from adjacent chambers. For achieving the above objects, the shape of a flow channel in a flow cell including a plate having micro-chambers is varied between the time of substance supply and the time of luminescence reaction.

The present invention relates to methods and compositions for the treatment and diagnosis of immune disorders, especially T helper lymphocyte-related disorders. For example, genes which are differentially expressed within and among T helper (TH) cells and TH cell subpopulations, which include, but are not limited to TH0, TH1 and TH2 cell subpopulations are identified. Genes are also identified via the ability of their gene products to interact with gene products involved in the differentiation, maintenance and effector function of such TH cells and TH cell subpopulations. The genes identified can be used diagnostically or as targets for therapeutic intervention. In this regard, the present invention provides methods for the identification and therapeutic use of compounds as treatments of immune disorders, especially TH cell subpopulation-related disorders. Additionally, methods are provided for the diagnostic evaluation and prognosis of TH cell subpopulation-related disorders, for the identification of subjects exhibiting a predisposition to such conditions, for monitoring patients undergoing clinical evaluation for the treatment of such disorders, and for monitoring the efficacy of compounds used in clinical trials.

Compositions and methods for making and using anti-LPA agents, for example, monoclonal antibodies, are described.

The invention discloses controlled-release antibiotic expanded acrylic bone cement prepared by mixing a solid phase and a liquid phase according to a ratio of 1g: (0.6ml-0.9ml), wherein the solid phase includes polymethyl methacrylate, antibiotic loaded microspheres with expandable core-shell structures and barium sulfate which are in the mass ratio of (5-7): (2.1-4.5): (0.5-0.9), and the antibiotic loaded microspheres with expandable core-shell structures contain carboxylated graphene; and the liquid phase includes methyl methacrylate, an accelerant and a retardant which are in the mass ratioof (8.5-9.5): (0.25-0.5): (0.25-1). The invention further discloses a preparation method of the controlled-release antibiotic expanded acrylic bone cement. The bone cement prepared by using the method has a better expansion ratio, also has a sensitive pH response function and is capable of realizing long-acting drug release as required according to the pH change of a microenvironment surroundingan implant, so that the release ratio of antibiotics is increased.

The invention relates to a novel composition for disinfecting nipple skins of dairy cows, in particular to a composition for disinfecting the nipple skins of the dairy cows before and after milking.

The invention relates to a gynecological collagen lotion and a preparation method thereof. The gynecological collagen lotion is prepared from 0.5-10% of glycerinum, 0.5-10% of propylene glycol, 0.5-10% of cocamidopropyl betaine, 0.01-0.2% of menthol, 0.01-0.1% of collagen, 0.01-2.0% of fructo-oligosaccharide, 0.1-2% of hydroxyethyl cellulose, 0.01-0.5% of polyhexamethylene biguanide hydrochloride,0.01-0.3% of ethylparaben, 1-5% of plant extracts, 0.01-2% of lactobacillus leavening and the balance of purified water till 100%. Due to adoption of the cocamidopropyl betaine and the plant extractsas main raw materials, and by virtue of synergetic functions of the raw materials and auxiliary materials, the gynecological collagen lotion which is good in treatment effect and free of irritation to vulvae can be prepared, and the product has remarkable antibacterial effects on escherichia coli, staphylococcus aureus, candida albicans and the like, and is capable of preventing propagation of harmful bacteria and maintaining cleanliness and health of the vulvae.

The invention relates to the field of autoimmune disease treatment based on lymphocyte B-stimulated factor receptor-antibody fusion protein, in particular to application of optimized TACI (Transmembrane Activator and CAML Interactor)-Fc fusion protein in the preparation of medicaments for treating rheumatoid arthritis. The medicament provided by the invention can be safely and effectively used for treating rheumatoid arthritis, and is beneficial to lowering the cost of such recombinant protein medicaments, thereby being suitable for industrial popularization and application.

The invention discloses acylated flavonoid glycoside compounds shown as a formula I and application thereof in preparation of complement inhibitor medicines. Acylated flavonoid glycosides extracted and separated from cudweed herb are proved to inhibit hemolysis caused by activation of a complement system in a classical pathway through in vitro experiments, and have complement inhibition effect; the activity of each monomericcompound is higher than that of a total extract of cudweed herb; and the acylated flavonoid glycoside compounds are good complement inhibitors and have low effective concentration, can serve as active ingredients to prepare novel complement inhibitor medicines for treating various diseases caused by abnormal activation of complements, are low in toxicity, safe in administration and rich in raw material sources and have great clinical application value. The structure of the formula I is shown as the specifications, wherein R1 and R2 are same or different, and respectively H, OH or OCH3; and R3 and R4 are respectively H or groups shown in the specifications.

The invention discloses stable bromochlorohydantoin disinfection liquid. The stable bromochlorohydantoin disinfection liquid comprises the following components in parts by weight: 1-20 parts of bromochlorohydantoin, 0.1-15 parts of a cosolvent, 1-10 parts of a stabilizing agent, 0.1-2 parts of a synergist, 1-5 parts of a pH regulating agent and 50-90 parts of water. The stable bromochlorohydantoin disinfection liquid has the beneficial effects that the stability is far superior to the use effects of similar disinfectants in the current market, the reduction of the effective concentration of the disinfection liquid is smaller than 10% after the disinfection liquid is put into a drying oven with temperature of 54 DEG C to be preserved for 14 days, and thus the disinfection liquid can meet the stability requirement of Ministry of Health on the disinfection liquid; a surface disinfection effect is enhanced; for achieving the preferable surface disinfection effect, the synergist is added to reduce the surface tension of the disinfection liquid to be below 40 dyne/cm, so that the disinfection liquid can well wet the surfaces of microorganisms to achieve the synergistic effect.

The invention discloses an application of sofosbuvir in preparation of medicines for preventing and treating coronavirus, and particularly discloses an application of sofosbuvir or a pharmaceuticallyacceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof in preparation of medicines for preventing and/or treating diseases caused by coronavirus. The coronaviruses are novel coronaviruses SARS-Cov-2, SARS-CoV, HCoV 229E, NL63, OC43, HKU1 and MERS-CoV. The half effective concentration of sofosbuvir on novel coronavirus of Corona Virus Disease 2019 is 1.12 [mu]M, the toxicity is low, and a good treatment window is provided.